General Dermatology

Galderma addresses menopause-related skin changes at IMCAS 2026, revealing survey insights and committing to inclusive clinical trials for better patient solutions.

Learn more about the in-depth topics covered in the January 2026 print issue of Dermatology Times.

Dermatology Times is recapping our exclusive expert interviews from the month of January.

Explore the nuances of off-label dermatology therapies, emphasizing evidence-based practices, patient communication, and ethical considerations for optimal care.

Litifilimab shows significant efficacy in improving skin outcomes for CLE, as demonstrated in the phase 2 LILAC study.

Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.

Bitopertin shows promise as a disease-modifying therapy for erythropoietic protoporphyria, significantly reducing PPIX levels and improving patient outcomes.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 delgocitinib in lichen sclerosus, amlitelimab's every-12-week dosing in AD, Galderma's phase 3 aesthetics data, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Belimumab shows significant long-term benefits for cutaneous lupus erythematosus, improving skin symptoms and maintaining efficacy.

The survey revealed significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive, long-term treatment strategies.

Explore the latest advancements in dermatology for 2026, focusing on clinical innovation, emerging research, and practical insights for improved patient care.

This review of the latest dermatologic studies includes insights on a novel ultrasound technique for midface rejuvenation, sirolimus for reducing cSCC risk, dermatologists' role in social media dysmorphia, and more.

Public interest in GLP-1 weight loss medications surges, revealing concerns about aesthetic effects like "Ozempic face" and prompting new treatment strategies.

Explore the latest dermatology trends for 2026, including innovative therapies for psoriasis, atopic dermatitis, and hair loss advancements.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the commercial launch of cosibelimab-ipdl, dupilumab in pediatric AD, a phase 3 trial of lebrikizumab in nummular eczema, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

This review of the latest dermatologic studies includes insights on the "fear of overfilling," sexual adverse events from oral finasteride, post-laser, fibronectin-based skin care regimens, and more.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 data of envudeucitinib for psoriasis, a combination treatment of ixekizumab and tirzepatide for PsA, a BLA pathway for sonelokimab in HS, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.

Johnson & Johnson's nipocalimab shows promise in reducing systemic lupus erythematosus activity, paving the way for a phase 3 development program.